Floatz logo

Ebv Mrna Vaccine

Advanced EBV-positive Malignant Solid Tumors

Sun Yat-sen UniversityvaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Advanced EBV-positive Malignant Solid Tumors cohort.

Asset / SponsorPhaseRating
Tabelecleucel
Atara Biotherapeutics
Phase 2B
Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes
Atara Biotherapeutics
Phase 1/2CCC
Ebv-Specific T Cells: B
Memorial Sloan Kettering Cancer Center
Phase 2CCC
Avelumab
Yonsei University
Phase 2CCC
qs-21
Ohio State University Comprehensive Cancer Center
Phase 1NR

Same molecule, other indications

Ebv Mrna Vaccine is also rated in:

HIV-associated cancerDormant
C
Indicative ·
39 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →